Alaunos Therapeutics, Inc. (TCRT) reported Q3 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $0 .
Alaunos Therapeutics, Inc. (TCRT) reported Q3 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $0 .